CLAIMS

[Claim 1]

A Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα radiation.

[Claim 2]

A Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα radiation.

[Claim 3]

A Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 9.3 degrees, 9.7 degrees, 16.8 degrees 20.6 degrees and 23.5 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Kα radiation.

[Claim 4]

A pharmaceutical composition comprising the crystal of any one of claims 1 to 3 as an active ingredient.

[Claim 5]

A PGI2 receptor agonist agent comprising the crystal of any one of claims 1 to 3 as an active ingredient.

[Claim 6]

A therapeutic agent for treatment of a condition selected from the group consisting of diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, thrombosis, pulmonary hypertension, myocardial infarction, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), scleroderma, chronic obstructive pulmonary disease, inflammatory bowel disease, tubulointerstitial nephritis, and symptoms associated with lumbar spinal canal stenosis, wherein the therapeutic agent comprises the crystal of any one of claims 1 to 3 as an active ingredient.

[Claim 7]

The therapeutic agent according to claim 6, wherein the condition is pulmonary hypertension.

[Claim 8]

The therapeutic agent according to claim 6, wherein the condition is circulatory disturbance.

[Claim 9]

The therapeutic agent according to claim 6, wherein the condition is chronic arterial occlusion.

[Claim 10]

The therapeutic agent according to claim 6, wherein the condition is intermittent claudication.

[Claim 11]

The therapeutic agent according to claim 6, wherein the condition is symptoms associated with spinal canal stenosis.

[Claim 12]

The therapeutic agent according to claim 6, wherein the condition is pulmonary fibrosis.

[Claim 13]

The therapeutic agent according to claim 6, wherein the condition is scleroderma.

[Claim 14]

The therapeutic agent according to claim 6, wherein the condition is chronic renal failure.

[Claim 15]

The therapeutic agent according to claim 6, wherein the condition is tubulointerstitial nephritis.